www.hivandhepatitis.com

EACS 2013: Anal Cancer Screening May Be Appropriate for All Women with HIV

Women living with HIV had a higher risk of anal pre-cancerous changes than cervical changes linked to human papillomavirus (HPV), French researchers reported at the 14th European AIDS Conference this week in Brussels. They suggested that all women with HIV ought to be screened routinely for pre-cancerous changes in the anal canal.

[Produced in collaboration with Aidsmap.com]

The study also found that there was no association between pre-cancerous changes in the anal canal and a prior history of anal intercourse, but a strong association with a previous history of cervical HPV-related disease.

Clinical management guidelines for women with HIV recommend routine screening for pre-cancerous cervical changes according to national guidelines. There is no consensus regarding anal screening in women with HIV.

French researchers carried out a study to determine the prevalence of anal HPV infection and pre-cancerous changes in the anus among women with HIV participating in a national cohort study. The study recruited 319 women who agreed to anal HPV screening, of whom 171 (54% of the cohort) consented to an anal examination by a proctologist. Women who declined to take part in the anal examination had significantly higher CD4 counts, a longer duration of HIV infection, and a higher frequency of viral suppression on antiretroviral treatment (98% of all participants were taking antiretroviral therapy).

The median age of women who took part in the study was 47 years, the median CD4 cell count 655 cells/mm³, and 36% were from sub-Saharan Africa. 36% of the women reported a prior history of receptive anal intercourse.

Women underwent cervical Pap and HPV testing and anal cytology and HPV testing. High-resolution anoscopy was performed in order to identify the stage of any lesions in the anal canal.

Anoscopy diagnosed anal lesions in 34% of women (21 of 171 samples were excluded due to unsatisfactory sampling). Low-grade anal intraepithelial neoplasia (AIN 1) was diagnosed in 21% of women and high-grade lesions (AIN 2-3) in 13% of women. One woman was diagnosed with anal cancer. A high prevalence of HPV types associated with cancer was detected (57%). Two-thirds of women with high-risk HPV sub-types had more than 1 high-risk sub-type.

The sensitivity of high-resolution anoscopy to detect high-grade anal intraepithelial neoplasia was 76% and the specificity was 61%.

By multivariate analysis, high-grade anal intraepithelial neoplasia (HGAIN) was associated with a history of cervical low-grade intraepithelial lesions (relative risk 4.0). HGAIN was more strongly associated with the detection of HPV-16 (relative risk 15.6).

In a comparison of cervical and anal cytology and HPV testing results, both low-grade lesions and high-risk HPV types were found to be more common in the anal canal.

This study was cross-sectional in design, and so evaluated only the prevalence of HPV-associated lesions and high-risk HPV types. The tendency of low-grade cervical lesions to regress during follow-up has led to uncertainty regarding the natural history of HPV-related anal lesions, so a prospective study which followed women for several years might lead to different estimates of risk. Nevertheless, the French research group concluded that their findings suggest that anal HPV screening may be warranted in all women with HIV.

High Prevalence of Pre-Cancerous Changes in Gay and Bisexual Men

European AIDS Clinical Society guidelines recommend anal screening by Pap smear for gay and bisexual men with HIV, but implementation of this guidance varies according to national screening recommendations and local resources.

A study of systematic anal screening in a cohort of gay and bisexual men attending the St. Pierre University Hospital clinic in Brussels found abnormalities by anal cytology in 48% of 382 analyzable samples (10% were excluded due to insufficient sampling), of which 19% were classified as ASCUS (atypical squamous cells of undetermined significance) and 4% as ASC-H (atypical squamous cells, cannot rule out high-grade lesions).

Biopsies were carried out for 118 of the 183 patients with abnormal cytology. 39% of these patients were found to have AIN 2 or 3 (46 out of 383 patients screened), an approximate prevalence of 18%.

The most significant risk factor for AIN 2-3 was a shorter duration of fully suppressed viral load (15 months versus 21 months in those without) and a nadir (lowest-ever) CD4 cell count below 100 cells/mm³. In multivariate analysis, nadir CD4 count emerged as the stronger predictor of AIN 2-3 (RR 2.8).

Comparing her results with those of other recent studies of AIN prevalence in men who have sex with men, presenter Agnés Libois said that other studies had shown higher prevalence, but that low nadir CD4 count has shown a consistent association with HGAIN and anal cancer across a number of studies.

Similarly, a longer duration of viral suppression on treatment has been associated with a lower risk of anal cancer in a number of studies in both men and women, she said. However, the extent to which earlier initiation of treatment might reduce the risk of anal cancer remains to be established, she concluded.

As in women, frequent regression of high-grade lesions has been observed in men who have sex with men.

These studies are unlikely to settle the ongoing debate regarding the cost-effectiveness of anal screening in men or women, but do highlight particular patient sub-groups who might be prioritized for screening.

10/18/13

References

I Heard, I Etienney, V Potard, et al. High prevalence of anal human papilloma virus infection and related cancer precursors in a contemporary cohort of asymptomatic HIV-infected women. 14th European AIDs Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS6/4.

A Libois, F Feoli, M Nkuize, et al. High prevalence of anal dysplasia in a cohort of HIV positive MSM enrolled in a systematic screening program: risk factors and positive impact of cART. 14th European AIDs Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS6/3.